Completed NA NCT00002021
An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies
Sponsor: Astra USA
Conditions
HIV Infections Herpes Simplex
Interventions
Foscarnet sodium
Updated 5 times since 2017 Last updated: Jun 23, 2005
Listed as NCT00002021, this NA trial focuses on HIV Infections and Herpes Simplex and remains completed. Sponsored by Astra USA, it has been updated 5 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Astra USA
Data source: NIH AIDS Clinical Trials Information Service
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Los Angeles, United States
- • Pasadena, United States